Literature DB >> 10556735

The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate.

H Larhrib1, X M Zeng, G P Martin, C Marriott, J Pritchard.   

Abstract

Five different grades of lactose namely, anhydrous lactose, medium lactose, regular lactose, lactose crystals and foremost lactose were fractionated under similar conditions to obtain a size range of 63-90 microm and were characterised using laser diffraction and time-of-flight particle sizing techniques, scanning electron microscopy, optical microscopy image analysis, thermal gravimetric analysis and differential scanning calorimetry. Each of these lactose fractions were then blended separately with micronised salbutamol sulphate in a ratio of 67.5:1 (w/w). The mixing uniformity and percentage recovery of salbutamol sulphate in the powder blends were analysed using a validated HPLC method. The deposition profiles of the drug were determined using a 5-stage liquid impinger after aerosolisation at 60 l min(-1) via a Rotahaler. Despite the identical processing conditions, the lactose fractions were shown to differ in particle size, size distribution and concentrations of fine particles. The particles from each fraction also exhibited different surface textures and dissimilar DSC thermograms. However, all the blends of the lactose with salbutamol sulphate were found to have a relatively high uniformity of salbutamol sulphate content, as suggested by a coefficient of variation of less than 3.2%. Anhydrous and medium lactose produced a more efficient delivery of salbutamol sulphate when aerosolised from the Rotahaler in comparison to other grades of lactose. For example, the fine particle fraction (FPF) and fine particle dose (FPD) of drug from formulations containing anhydrous lactose were 13.4+/-4.2% and 57.3+/-17.6 microg, respectively, which were approximately two times higher than the respective values of the formulation containing regular lactose. Medium lactose resulted in drug FPF (7. 9+/-2.7%) and FPD (32.4+/-11.8 microg), which were significantly (ANOVA P<0.05) higher than the same parameters obtained using lactose crystals, foremost lactose and regular lactose. More efficient drug delivery from anhydrous lactose may be partly attributed to the relatively higher concentration of fine lactose in this grade of carrier, although it showed a rougher surface than the other grades of lactose. However, the relatively high FPF of the drug from medium lactose may have been due to the relatively small mean particle size and smooth surface of the particles. Therefore, the source and grade of lactose may have a substantial effect on drug delivery from dry powder inhaler formulations and care should be taken in establishing appropriate quality control parameters when selecting an appropriate grade of carrier.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10556735     DOI: 10.1016/s0378-5173(99)00164-7

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  16 in total

1.  Predicting the quality of powders for inhalation from surface energy and area.

Authors:  David Cline; Richard Dalby
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

2.  Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate.

Authors:  V N P Le; T H Hoang Thi; E Robins; M P Flament
Journal:  AAPS PharmSciTech       Date:  2012-03-08       Impact factor: 3.246

3.  Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration.

Authors:  Vanna Sanna; Nathalie Kirschvink; Pascal Gustin; Elisabetta Gavini; Isabelle Roland; Luc Delattre; Brigitte Evrard
Journal:  AAPS PharmSciTech       Date:  2004-03-10       Impact factor: 3.246

4.  The cohesive-adhesive balances in dry powder inhaler formulations II: influence on fine particle delivery characteristics.

Authors:  Philippe Begat; David A V Morton; John N Staniforth; Robert Price
Journal:  Pharm Res       Date:  2004-10       Impact factor: 4.200

5.  The rate of drug particle detachment from carrier crystals in an air classifier-based inhaler.

Authors:  Anne H de Boer; Paul Hagedoorn; Doetie Gjaltema; Dorette Lambregts; Meike Irngartinger; Henderik W Frijlink
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

Review 6.  The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations.

Authors:  Matthew D Jones; Robert Price
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

7.  Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalers.

Authors:  Waseem Kaialy; Gary P Martin; Martyn D Ticehurst; Paul Royall; Mohammad A Mohammad; John Murphy; Ali Nokhodchi
Journal:  AAPS J       Date:  2010-11-06       Impact factor: 4.009

8.  Formulation and evaluation of carrier-free dry powder inhaler containing sildenafil.

Authors:  Thi-Tram Nguyen; Eun-Jin Yi; Kyu-Mok Hwang; Cheol-Hee Cho; Chun-Woong Park; Ju-Young Kim; Yun-Seok Rhee; Eun-Seok Park
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

9.  Lactose surface modification by decantation: are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixtures?

Authors:  Nazrul Islam; Peter Stewart; Ian Larson; Patrick Hartley
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

Review 10.  Nanomedicine in pulmonary delivery.

Authors:  Heidi M Mansour; Yun-Seok Rhee; Xiao Wu
Journal:  Int J Nanomedicine       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.